Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myrialen is a branded sterile ophthalmic gel medical device containing 5% dexpanthenol, used to hydrate, lubricate, and protect the corneal and conjunctival epithelium in patients with dry eye, ocular irritation, burning, or foreign body sensation due to environmental or other noninfectious causes.[1][3][4][7] Dexpanthenol (provitamin B5) is converted in ocular tissues to pantothenic acid, a component of coenzyme A involved in epithelial metabolism and repair, supporting corneal surface healing and maintaining tear film stability.[1][3][4] The gel vehicle (with carbomer and excipients) prolongs residence time on the ocular surface, providing sustained symptom relief, and Myrialen has been evaluated in a randomized clinical investigation versus another 5% dexpanthenol gel (Recugel) in patients with moderate to severe dry eye syndrome.[3][5][13][14]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Myrialen.